Taysha Gene Therapies (TSHA)

P/S ratio as of November 2026 (TTM): 245

According to Taysha Gene Therapies's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.47. At the end of 2026 the company had a P/S ratio of 332.

P/S ratio history for Taysha Gene Therapies from 2020 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	332	125.73%
2025	147	241.89%
2024	43.0	100.96%
2023	21.4	-62.03%
2022	56.4
2021	N/A
2020	N/A

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
ORIC Pharmaceuticals ORIC	N/A	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Taysha Gene Therapies (TSHA)

P/S ratio as of November 2026 (TTM): 245